<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840970</url>
  </required_header>
  <id_info>
    <org_study_id>P500-0208</org_study_id>
    <nct_id>NCT00840970</nct_id>
  </id_info>
  <brief_title>A Clinical Evaluation of the Sinexus Intranasal Splint Following Functional Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis</brief_title>
  <acronym>CONSENSUS II</acronym>
  <official_title>A Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Rhinosinusitis (CRS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intersect ENT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intersect ENT</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and performance of the Sinexus Intranasal&#xD;
      Splint when used following Functional Endoscopic Sinus Surgery (FESS) in patients with&#xD;
      Chronic Rhinosinusitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, multi-center, double blind trial that enrolled patients in three&#xD;
      groups as described below. Two groups (Pilot 15 mm and Efficacy 25 mm) used a randomized,&#xD;
      double-blind, intra-patient control study design to assess performance of the drug-coated&#xD;
      Splint (received in one ethmoid sinus) compared to the control Splint (received in the&#xD;
      contralateral ethmoid). The other group of patients (Safety/PK 25 mm) received bilateral&#xD;
      drug-coated Splints, and served as a pharmacokinetics (PK) study group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intra-patient control where one ethmoid sinus was randomized to receive the intervention (treatment arm) while the contralateral ethmoid received the active comparator (control arm)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device Success Rate</measure>
    <time_frame>Baseline</time_frame>
    <description>Device success rate defined as a ratio where the numerator is the number of successful deployments of the Sinexus Intranasal Splint and the denominator is the number of attempted sinuses. Deployment was considered successful if the implant procedure concluded with a successful splint placement on the intended side.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in Ethmoid Sinus Inflammation</measure>
    <time_frame>21 days</time_frame>
    <description>Inflammation was scored by the physician using a 100-mm Visual Analog Scale (VAS) during endoscopic evaluation with range of 0 to 100mm. The term inflammation was used as a global descriptor defined to include mucosal edema, erythema, hypertrophy and polypoid changes. 0 represented no inflammation and 100mm was defined as &quot;Severe, involving significant and extensive erythema and edema and/or hypertrophy and/or polypoid changes&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Middle Turbinate Lateralization</measure>
    <time_frame>30 days</time_frame>
    <description>Position of the middle turbinate was assessed using a 4-point categorical scale (medialized, normal, partially lateralized, lateralized). For Lateralized Middle Turbinate, a sinus is counted once if this occurs at least once during the 30 Day timeframe. Lateralized Middle Turbinate (worse outcome), if left unaddressed, is often the cause of sinus obstruction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Middle Meatus Patency</measure>
    <time_frame>30 days</time_frame>
    <description>Patency of the middle meatus was assessed using a 3-point categorical scale (patent, narrowed, obstructed). Analysis included patent (better outcome) vs narrowed/obstructed (worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant Adhesion Occurrence</measure>
    <time_frame>30 days</time_frame>
    <description>Adhesion formation was assessed using a 5-point categorical scale (none, small/non-obstructing, obstructing/easily separated, *dense/obstructing/difficult to separate, *severe/complete adhesion to lateral nasal wall) with &quot;significant adhesion&quot; denoted by *</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polypoid Tissue Changes</measure>
    <time_frame>30 days</time_frame>
    <description>Polyp formation in the ethmoid sinus assessed using an accepted 5-point categorical scale: 0-no visible nasal polyp (NP), 1-small amount NP confined in the middle meatus (MM); 2-multiple NP confined in MM; 3-NP extending beyond MM, within the sphenoethmoid recess not totally obstructing, or both; 4-NP completely obstructing the nasal cavity. 0 is best, and 4 is worst. When a patient's sinus has a change in polyp score at Day 30 it is counted as one.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Sinusitis</condition>
  <arm_group>
    <arm_group_label>Efficacy Unilateral Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator following FESS (control arm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efficacy Unilateral Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the intervention following FESS (treatment arm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety/PK Bilateral Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug-coated splints placed bilaterally in both ethmoid sinus openings following FESS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>non-coated Intranasal Splint</intervention_name>
    <description>placement of non-coated intranasal splint following FESS</description>
    <arm_group_label>Efficacy Unilateral Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sinexus Intranasal Splint</intervention_name>
    <description>placement of Sinexus Intranasal Splint placed following FESS</description>
    <arm_group_label>Efficacy Unilateral Treatment</arm_group_label>
    <arm_group_label>Safety/PK Bilateral Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is 18 years of age or older.&#xD;
&#xD;
          -  Patient has a diagnosis of bilateral CRS defined as inflammation of the mucosa of the&#xD;
             nose and paranasal sinuses of at least 12 consecutive weeks' duration.&#xD;
&#xD;
          -  Patient has a clinical indication for and has consented to bilateral FESS.&#xD;
&#xD;
          -  CRS diagnosis documented by CT scan within 60 days of the procedure.&#xD;
&#xD;
          -  Patient has minimal total CT stage (Lund-Mackay method) of 6.&#xD;
&#xD;
          -  Patient has bilateral disease defined as minimal CT stage per side of â‰¥3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Oral-Steroid dependent COPD, asthma or other condition.&#xD;
&#xD;
          -  Immune deficiency (IGG subclass deficiency or IGA deficiency).&#xD;
&#xD;
          -  Symptomatic coronary artery disease.&#xD;
&#xD;
          -  Patient undergoing chemotherapy treatment.&#xD;
&#xD;
          -  Morbid obesity (BMI &gt; 40) or a BMI that, in the opinion of the physician, would&#xD;
             compromise health and participation in the study.&#xD;
&#xD;
          -  Evidence of active infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent Lanier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central California Ear, Nose, Throat</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central California Ear, Nose, Throat</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 9, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <results_first_submitted>August 12, 2020</results_first_submitted>
  <results_first_submitted_qc>September 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2020</results_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pilot 15 mm</title>
          <description>First 7 patients (n=7) in the Pilot Phase received 15 mm length splint. This phase used a randomized intra-patient design wherein following FESS a non-coated splint was placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator (control arm), and the drug-coated Sinexus Splint (15mm length, 220 ug mometasone furoate [MF]) was placed contralaterally in the ethmoid sinus opening randomized to receive the intervention (treatment arm). 15 mm length splint was not commercialized.</description>
        </group>
        <group group_id="P2">
          <title>Efficacy 25 mm</title>
          <description>Efficacy group received the 25mm splint in the Pilot (n=13) and Pivotal Phases (n=25).&#xD;
Both phases used a randomized intra-patient design wherein following FESS a non-coated splint was placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator (control arm), and the drug-coated Sinexus Splint (25 mm length, 370 ug MF) was placed contralaterally in the ethmoid sinus opening randomized to receive the intervention (treatment arm).</description>
        </group>
        <group group_id="P3">
          <title>Safety/PK 25 mm</title>
          <description>Safety/PK group (n=5) used a non-randomized design wherein following FESS a drug-coated splints (25 mm length with 370 ug MF) were placed bilaterally in both ethmoid sinus openings.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis prespecified for Efficacy 25 mm (Pivotal n=25) and all patients only. They cannot be specified per group.</population>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>All Patients includes the Pilot 15 mm (n=7), Efficacy 25 mm (n=38 [Pilot n=13,Pivotal Phases n=25]) and Safety/PK 25 mm (n=5) groups.&#xD;
Pilot 15 mm and Efficacy 25 mm groups used a randomized intra-patient design wherein following FESS a non-coated splint was placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator (control arm), and the drug-coated Sinexus Splint was placed contralaterally in the ethmoid sinus opening randomized to receive the intervention (treatment arm). In Pilot 15 mm group, patients in treatment arm received a 15mm length splint (220ug MF). In Efficacy 25 mm group, patients in the treatment arm received a 25mm length splint (370ug MF).&#xD;
Safety/PK group used a non-randomized design wherein following FESS a drug-coated splints (25 mm length with 370 ug MF) were placed bilaterally in both ethmoid sinus openings.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous smoker, stopped &gt; 1 year ago</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptoms pre-op</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Nasal obstruction/congestion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discolored nasal discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dental pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Halitosis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear pain, pressure, fullness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anosmia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial pain, pressure, other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of prior sinus procedures</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lund-Mackay score</title>
          <description>The Lund-Mackay score is used to assess chronic rhinosinusitis. Each sinus (frontal, anterior ethmoidal cells, posterior ethmoidal cells, maxillary sinus, and sphenoid sinus) is scored from 0 (no abnormality), 1 (partial opacification) to 2 (complete opacification). The ostiomeatal complex is scored from 0 (not obstructed) to 2 (obstructed). Each side is graded separately. A combined score of up to 24 is possible.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Right</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.6" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Polyps</title>
          <description>Polyps at baseline is defined as either the right or left ethmoid having a polyp grade &gt; 0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Device Success Rate</title>
        <description>Device success rate defined as a ratio where the numerator is the number of successful deployments of the Sinexus Intranasal Splint and the denominator is the number of attempted sinuses. Deployment was considered successful if the implant procedure concluded with a successful splint placement on the intended side.</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis per patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot 15 mm</title>
            <description>First 7 patients (n=7) in the Pilot Phase received 15 mm length splint. This phase used a randomized intra-patient design wherein following FESS a non-coated splint was placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator (control arm), and the drug-coated Sinexus Splint (15mm length, 220 ug mometasone furoate [MF]) was placed contralaterally in the ethmoid sinus opening randomized to receive the intervention (treatment arm). 15 mm length splint was not commercialized.</description>
          </group>
          <group group_id="O2">
            <title>Efficacy 25 mm</title>
            <description>Efficacy group received the 25mm splint in the Pilot (n=13) and Pivotal Phases (n=25).&#xD;
Both phases used a randomized intra-patient design wherein following FESS a non-coated splint was placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator (control arm), and the drug-coated Sinexus Splint (25 mm length, 370 ug MF) was placed contralaterally in the ethmoid sinus opening randomized to receive the intervention (treatment arm).</description>
          </group>
          <group group_id="O3">
            <title>Safety/PK 25 mm</title>
            <description>Safety/PK group (n=5) used a non-randomized design wherein following FESS a drug-coated splints (25 mm length with 370 ug MF) were placed bilaterally in both ethmoid sinus openings.</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success Rate</title>
          <description>Device success rate defined as a ratio where the numerator is the number of successful deployments of the Sinexus Intranasal Splint and the denominator is the number of attempted sinuses. Deployment was considered successful if the implant procedure concluded with a successful splint placement on the intended side.</description>
          <population>Analysis per patient.</population>
          <units>ethmoid sinuses</units>
          <param>Count of Units</param>
          <units_analyzed>ethmoid sinuses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ethmoid sinuses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Ethmoid Sinus Inflammation</title>
        <description>Inflammation was scored by the physician using a 100-mm Visual Analog Scale (VAS) during endoscopic evaluation with range of 0 to 100mm. The term inflammation was used as a global descriptor defined to include mucosal edema, erythema, hypertrophy and polypoid changes. 0 represented no inflammation and 100mm was defined as &quot;Severe, involving significant and extensive erythema and edema and/or hypertrophy and/or polypoid changes&quot;.</description>
        <time_frame>21 days</time_frame>
        <population>This measure only analyzed for Efficacy 25 mm splint (n=38). Efficacy 15 mm splint (n=7) not analyzed since it was not commercialized. Safety/PK (n=5) only evaluated for safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Efficacy (Treatment Arm, 25 mm)</title>
            <description>This group includes all ethmoid sinuses that received the 25 mm drug-coated Sinexus intranasal splint in Efficacy (Pilot Phase n=13, Pivotal Phase n=25).</description>
          </group>
          <group group_id="O2">
            <title>Efficacy (Control Arm, 25 mm)</title>
            <description>This group includes all ethmoid sinuses that received the 25 mm non-coated Sinexus intranasal splint in Efficacy (Pilot Phase n=13, Pivotal Phase n=25).</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Ethmoid Sinus Inflammation</title>
          <description>Inflammation was scored by the physician using a 100-mm Visual Analog Scale (VAS) during endoscopic evaluation with range of 0 to 100mm. The term inflammation was used as a global descriptor defined to include mucosal edema, erythema, hypertrophy and polypoid changes. 0 represented no inflammation and 100mm was defined as &quot;Severe, involving significant and extensive erythema and edema and/or hypertrophy and/or polypoid changes&quot;.</description>
          <population>This measure only analyzed for Efficacy 25 mm splint (n=38). Efficacy 15 mm splint (n=7) not analyzed since it was not commercialized. Safety/PK (n=5) only evaluated for safety data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>ethmoid sinuses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ethmoid sinuses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="17.7"/>
                    <measurement group_id="O2" value="35.3" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Middle Turbinate Lateralization</title>
        <description>Position of the middle turbinate was assessed using a 4-point categorical scale (medialized, normal, partially lateralized, lateralized). For Lateralized Middle Turbinate, a sinus is counted once if this occurs at least once during the 30 Day timeframe. Lateralized Middle Turbinate (worse outcome), if left unaddressed, is often the cause of sinus obstruction.</description>
        <time_frame>30 days</time_frame>
        <population>This measure only analyzed for Efficacy 25 mm splint (n=38). Efficacy 15 mm splint (n=7) not analyzed since it was not commercialized. Safety/PK (n=5) only evaluated for safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Efficacy (Treatment Arm, 25 mm)</title>
            <description>This group includes all ethmoid sinuses that received the 25 mm drug-coated Sinexus intranasal splint in Efficacy (Pilot Phase n=13, Pivotal Phase n=25).</description>
          </group>
          <group group_id="O2">
            <title>Efficacy (Control Arm, 25 mm)</title>
            <description>This group includes all ethmoid sinuses that received the 25 mm non-coated Sinexus intranasal splint in Efficacy (Pilot Phase n=13, Pivotal Phase n=25).</description>
          </group>
        </group_list>
        <measure>
          <title>Middle Turbinate Lateralization</title>
          <description>Position of the middle turbinate was assessed using a 4-point categorical scale (medialized, normal, partially lateralized, lateralized). For Lateralized Middle Turbinate, a sinus is counted once if this occurs at least once during the 30 Day timeframe. Lateralized Middle Turbinate (worse outcome), if left unaddressed, is often the cause of sinus obstruction.</description>
          <population>This measure only analyzed for Efficacy 25 mm splint (n=38). Efficacy 15 mm splint (n=7) not analyzed since it was not commercialized. Safety/PK (n=5) only evaluated for safety data.</population>
          <units>ethmoid sinuses</units>
          <param>Count of Units</param>
          <units_analyzed>ethmoid sinuses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ethmoid sinuses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Middle Meatus Patency</title>
        <description>Patency of the middle meatus was assessed using a 3-point categorical scale (patent, narrowed, obstructed). Analysis included patent (better outcome) vs narrowed/obstructed (worse outcome).</description>
        <time_frame>30 days</time_frame>
        <population>This measure only analyzed for Efficacy 25 mm splint (n=38). Efficacy 15 mm splint (n=7) not analyzed since it was not commercialized. Safety/PK (n=5) only evaluated for safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Efficacy (Treatment Arm, 25 mm)</title>
            <description>This group includes all ethmoid sinuses that received the 25 mm drug-coated Sinexus intranasal splint in Efficacy (Pilot Phase n=13, Pivotal Phase n=25).</description>
          </group>
          <group group_id="O2">
            <title>Efficacy (Control Arm, 25 mm)</title>
            <description>This group includes all ethmoid sinuses that received the 25 mm non-coated Sinexus intranasal splint in Efficacy (Pilot Phase n=13, Pivotal Phase n=25).</description>
          </group>
        </group_list>
        <measure>
          <title>Middle Meatus Patency</title>
          <description>Patency of the middle meatus was assessed using a 3-point categorical scale (patent, narrowed, obstructed). Analysis included patent (better outcome) vs narrowed/obstructed (worse outcome).</description>
          <population>This measure only analyzed for Efficacy 25 mm splint (n=38). Efficacy 15 mm splint (n=7) not analyzed since it was not commercialized. Safety/PK (n=5) only evaluated for safety data.</population>
          <units>ethmoid sinuses</units>
          <param>Count of Units</param>
          <units_analyzed>ethmoid sinuses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ethmoid sinuses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Significant Adhesion Occurrence</title>
        <description>Adhesion formation was assessed using a 5-point categorical scale (none, small/non-obstructing, obstructing/easily separated, *dense/obstructing/difficult to separate, *severe/complete adhesion to lateral nasal wall) with &quot;significant adhesion&quot; denoted by *</description>
        <time_frame>30 days</time_frame>
        <population>This measure only analyzed for Efficacy 25 mm splint (n=38). Efficacy 15 mm splint (n=7) not analyzed since it was not commercialized. Safety/PK (n=5) only evaluated for safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Efficacy (Treatment Arm, 25 mm)</title>
            <description>This group includes all ethmoid sinuses that received the 25 mm drug-coated Sinexus intranasal splint in Efficacy (Pilot Phase n=13, Pivotal Phase n=25).</description>
          </group>
          <group group_id="O2">
            <title>Efficacy (Control Arm, 25 mm)</title>
            <description>This group includes all ethmoid sinuses that received the 25 mm non-coated Sinexus intranasal splint in Efficacy (Pilot Phase n=13, Pivotal Phase n=25).</description>
          </group>
        </group_list>
        <measure>
          <title>Significant Adhesion Occurrence</title>
          <description>Adhesion formation was assessed using a 5-point categorical scale (none, small/non-obstructing, obstructing/easily separated, *dense/obstructing/difficult to separate, *severe/complete adhesion to lateral nasal wall) with &quot;significant adhesion&quot; denoted by *</description>
          <population>This measure only analyzed for Efficacy 25 mm splint (n=38). Efficacy 15 mm splint (n=7) not analyzed since it was not commercialized. Safety/PK (n=5) only evaluated for safety data.</population>
          <units>ethmoid sinuses</units>
          <param>Count of Units</param>
          <units_analyzed>ethmoid sinuses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ethmoid sinuses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Polypoid Tissue Changes</title>
        <description>Polyp formation in the ethmoid sinus assessed using an accepted 5-point categorical scale: 0-no visible nasal polyp (NP), 1-small amount NP confined in the middle meatus (MM); 2-multiple NP confined in MM; 3-NP extending beyond MM, within the sphenoethmoid recess not totally obstructing, or both; 4-NP completely obstructing the nasal cavity. 0 is best, and 4 is worst. When a patient's sinus has a change in polyp score at Day 30 it is counted as one.</description>
        <time_frame>30 days</time_frame>
        <population>This measure only analyzed for Efficacy 25 mm splint (n=38). Efficacy 15 mm splint (n=7) not analyzed since it was not commercialized. Safety/PK (n=5) only evaluated for safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Efficacy (Treatment Arm, 25 mm)</title>
            <description>This group includes all ethmoid sinuses that received the 25 mm drug-coated Sinexus intranasal splint in Efficacy (Pilot Phase n=13, Pivotal Phase n=25).</description>
          </group>
          <group group_id="O2">
            <title>Efficacy (Control Arm, 25 mm)</title>
            <description>This group includes all ethmoid sinuses that received the 25 mm non-coated Sinexus intranasal splint in Efficacy (Pilot Phase n=13, Pivotal Phase n=25).</description>
          </group>
        </group_list>
        <measure>
          <title>Polypoid Tissue Changes</title>
          <description>Polyp formation in the ethmoid sinus assessed using an accepted 5-point categorical scale: 0-no visible nasal polyp (NP), 1-small amount NP confined in the middle meatus (MM); 2-multiple NP confined in MM; 3-NP extending beyond MM, within the sphenoethmoid recess not totally obstructing, or both; 4-NP completely obstructing the nasal cavity. 0 is best, and 4 is worst. When a patient's sinus has a change in polyp score at Day 30 it is counted as one.</description>
          <population>This measure only analyzed for Efficacy 25 mm splint (n=38). Efficacy 15 mm splint (n=7) not analyzed since it was not commercialized. Safety/PK (n=5) only evaluated for safety data.</population>
          <units>ethmoid sinuses</units>
          <param>Count of Units</param>
          <units_analyzed>ethmoid sinuses</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>ethmoid sinuses</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>Serious Adverse Local Tissue (SALT) response is defined as an adverse effect (bleeding, burning, or infection) occurring in the tissue of the splinted sinus cavity that is serious enough in nature or intensity as to require removal of the Sinexus intranasal splint to resolve.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pilot 15 mm</title>
          <description>First 7 patients (n=7) in the Pilot Phase received 15 mm length splint. This phase used a randomized intra-patient design wherein following FESS a non-coated splint was placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator (control arm), and the drug-coated Sinexus Splint (15mm length, 220 ug mometasone furoate [MF]) was placed contralaterally in the ethmoid sinus opening randomized to receive the intervention (treatment arm). 15 mm length splint was not commercialized.</description>
        </group>
        <group group_id="E2">
          <title>Efficacy 25 mm</title>
          <description>Efficacy group received the 25mm splint in the Pilot (n=13) and Pivotal Phases (n=25).&#xD;
Both phases used a randomized intra-patient design wherein following FESS a non-coated splint was placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator (control arm), and the drug-coated Sinexus Splint (25 mm length, 370 ug MF) was placed contralaterally in the ethmoid sinus opening randomized to receive the intervention (treatment arm).</description>
        </group>
        <group group_id="E3">
          <title>Safety/PK 25 mm</title>
          <description>Safety/PK group (n=5) used a non-randomized design wherein following FESS a drug-coated splints (25 mm length with 370 ug MF) were placed bilaterally in both ethmoid sinus openings.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chris Lewis, VP Clinical Affairs</name_or_title>
      <organization>Intersect ENT</organization>
      <phone>423-598-6681</phone>
      <email>clewis@intersectent.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

